**U.** **FMUP**

**FACULDADE DE MEDICINA**
UNIVERSIDADE DO PORTO

## MESTRADO INTEGRADO EM MEDICINA

2011/2012

Sara Dharmisha Fernandes da Silva Ranchordás

# In-hospital cardiac arrest: predictive factors and outcome

**março, 2012**

FMUP

Sara Dharmisha Fernandes da Silva Ranchordás

In-hospital cardiac arrest: predictive factors and outcome

**Mestrado Integrado em Medicina**

**Área: Cardiologia**

**Trabalho efetuado sob a Orientação de:**

**Prof. Doutor Manuel Joaquim Lopes Vaz da Silva**

**E sob a Coorientação de:**

**Dr. Luís Miguel Pereira Moreira Teixeira Lopes**

**Trabalho organizado de acordo com as normas da revista:**

Resuscitation

**março, 2012**

FMUP

**U.**PORTO

FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

UNIDADE CURRICULAR
**PROJETO DE OPÇÃO**
DISSERTAÇÃO / MONOGRAFIA

**Projeto de Opção do 6º ano - DECLARAÇÃO DE INTEGRIDADE**

Eu, Sara Dharmisha Fernandes da Silva Ranchordás, abaixo assinado, nº mecanográfico 060801129, estudante do 6º ano do Mestrado Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, _1_/_03_/_2012_

Assinatura: _Sara Dharmisha Fernandes da Silva Ranchordás_

**Nome:** Sara Dharmisha Fernandes da Silva Ranchordás

**Endereço eletrónico:** med06129@med.up.pt     **Telefone ou Telemóvel:** 913384368

**Número do Bilhete de Identidade:** 13353672

**Título da Dissertação:**

In-hospital cardiac arrest: predictive factors and outcome

**Orientador:**

Manuel Joaquim Lopes Vaz da Silva

**Ano de conclusão:** 2012

**Designação da área do projeto:**

Cardiologia

É autorizada a reprodução integral desta Dissertação para efeitos de investigação e de divulgação pedagógica, em programas e projectos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 2 / 03 / 2012

Assinatura: _Sara Dharmisha Fernandes da Silva Ranchordás_

# In-hospital cardiac arrest: predictive factors and outcome

**Author:** Sara Dharmisha Fernandes da Silva Ranchordás

6th year medical student at Faculty of Medicine of Porto, Porto, Portugal

Cardiology Department, Faculty of Medicine of Porto, University of Porto,

Al. Prof. Hernâni Monteiro, 4200 – 319, Porto, Portugal

Tel.: +351 22 551 3600; fax: +351 22 551 3601

Email address: med06129@med.up.pt


**Corresponding author at:**

Sara Dharmisha Fernandes da Silva Ranchordás

Cardiology Department, Faculty of Medicine of Porto, University of Porto,

Al. Prof. Hernâni Monteiro, 4200 – 319, Porto, Portugal

Tel.: +351 22 551 3600; fax: +351 22 551 3601

Email address: med06129@med.up.pt

**Word count:**

- **Abstract:** 250

- **Paper:** 2999

# Abstract

*Aim:* To assess comorbidities of patients who suffer a cardiac arrest in the hospital; immediate clinical antecedents of arrest and outcomes for all patients and to compare between monitored vs. unmonitored and dead vs. alive at discharge.

*Methods:* Patients admitted to the hospital in 2009, ≥ 18 years old, with in-hospital cardiac arrest >24hours after admission were included. T student test was performed for continuous variables; χ2 tests for categorical data and Mann—Whitney U-test for non-normal, continuous data.

*Results:* A total of 66 patients were included. The survival to discharge was 30.3%. Return of spontaneous circulation occurred in 88% of patients. One year survival of those discharged alive was around 55-85%. Only 6% did not have pre-existing morbidities. Over 80% of patients had clinical anomalies <24h prior to arrest. Forty (60.6%) patients were monitored and 26 (39.4%) were unmonitored. Most patients with a cardiac illness were monitored at the time of the event (p=0.02). Forty-six (69.7%) patients died in-hospital and 20 (30.3%) were discharged alive. The mean in-hospital days after cardiac arrest was significantly higher in survivors than in non-survivors (p=0.01). Non-survivors received defibrillation more frequently than survivors (*p=* 0.02).

*Conclusion:* Most patients that suffer in-hospital cardiac arrest have pre-existing morbidities and abnormal observations preceding cardiac arrest. There were no significant differences between monitored and unmonitored patients, except for illness category. We could not find distinctive characteristics between patients who died in-hospital and those who survived, except for a longer in-hospital stay for survivors and more frequent defibrillation in non-survivors.

**Keywords:** in-hospital cardiac arrest, outcome, morbidity, Charlson score, clinical antecedents, monitored.

## Introduction

The history of modern cardiopulmonary resuscitation (CPR) dates back to the 1960s, when methods of closed chest cardiac massage were first described.[1] In 1963, the American Heart Association formally endorsed CPR, which became an integral part of care in all patients facing imminent death.[2] In Portugal, the Portuguese Resuscitation Council was established in 1998.[3]

CPR is an attempt to restore spontaneous circulation by performing chest compressions with or without ventilations.[4]

Cardiac arrest can be defined as the cessation of cardiac mechanical activity as confirmed by the absence of signs of circulation.[4] According to the Utstein criteria, a cardiac arrest is classified as 'in-hospital' if it occurs in a hospitalised patient who had a pulse at the time of admission.[5]

In 1977, the survival to discharge after in-hospital cardiac arrest was 8.7%.[6] Nowadays, survival remains low, typically ranging from 15 to 23%.[7] Among those who are successfully resuscitated, between 25% and 67% die during the first 24 hours after return of spontaneous circulation (ROSC). One year after the arrest, reported survival of the originally discharged patients ranges between 53% and 86%.[5]

The three most common reasons for in-hospital cardiac arrest in adults are cardiac arrhythmia, acute respiratory insufficiency, and hypotension.[8] Studies have shown evidence of abnormal clinical signs in up to 80% of patients during the hours preceding the cardiac arrest.[5,7] The observation of deterioration in clinical condition of patients prior to cardiac arrest supports the idea that it is neither a sudden nor unpredictable event.[9]

Furthermore, three-quarters of adult survivors of CPR have one or more co-existing conditions, such as cardiac disease, cancer or diabetes.[10]

The main goals of this study were to assess: comorbidities of patients who suffer a cardiac arrest in the hospital; immediate clinical antecedents of arrest and the outcomes for all patients and to compare between monitored vs. unmonitored and dead vs. alive at discharge.

## Methods

### Data collection

All patients admitted to the hospital in 2009 and which were attributed the code "cardiac arrest" were included and their files were reviewed as well as copies of the death certificates of patients who died in the hospital, and, whenever available, charts of the medical emergency team (MET) were also analyzed. The post-discharge data was obtained through consultation of registries of later admissions or appointments at the hospital. The ethics committee of the Hospital S. João approved this study.

The information was collected according to the Utstein style guidelines, developed for reviewing, reporting, and conducting research on in-hospital resuscitation.[8]

In addition, the records were reviewed in order to allow the calculation of the Charlson age-comorbidity index, which is the most extensively studied comorbidity index. It encompasses 19 medical conditions selected and weighted 1–6 on the basis of the strength of their association with mortality, with total scores ranging from 0–37.[11-13]

### Inclusion criteria:

All adult (≥18 years of age) patients, who experience a resuscitation event were eligible for inclusion. A resuscitation event is defined as an acute respiratory compromise that requires emergency assisted ventilation leading to cardiopulmonary arrest that requires chest compressions and/or defibrillation, or cardiopulmonary arrest that requires chest compressions and/or defibrillation, and elicits an emergency resuscitation response by facility personnel, and a resuscitation record is completed for the event.[8]

### Exclusion criteria:

The following events were excluded: individuals who did not fulfil the inclusion criteria above and events that occurred less than 24hours after admission in the hospital, because the medical records, especially of those who die are generally incomplete and it is not possible to evaluate objectively clinical anomalies that occurred during the hours that preceded the arrest and which constituted a point of interest to this study.

For statistical purposes when a patient had more than one cardiac arrest, only the first episode was considered.

**Definition of end of event**

The end of an event is defined as ROSC lasting >20 min or the termination of the resuscitation event with the patient declared dead due to being unresponsive to resuscitative efforts or a medical futility advance directive (DNR - Do Not Resuscitate).[8] Sustained ROSC is defined as the single, continuous presence of palpable pulses for > 20 minutes.[14]

**Definition of monitored events**

Monitored events were those for which the patient had electrocardiographic or pulse oximetry monitoring in place at the time of arrest.

**Statistical analysis**

Descriptive statistics were computed for patient and event characteristics. Frequencies and percentages are presented for categorical data; medians with inter-quartile ranges are reported for non-normal, continuous data; t student test was performed to compare between pairs of continuous variables. Differences among the categories of monitored status were tested using $\chi2$ tests for categorical data and Mann—Whitney U-test for non-normal, continuous data. Ninety-five percent confidence intervals were calculated for odds ratios (OR) and for relative risk (RR). Analyses were performed in GraphPad Prism 5 ®. Statistical significance was defined as $p < 0.05$.

# Results

A total of 149 results were retrieved from the codification centre search and the respective files were analyzed. Among these, 31 were excluded because the arrests had occurred outside the hospital or in patients younger than 18 years old, 1 was excluded because the diagnosis in the medical records was of peri-arrest, with no evidence of an actual arrest. Finally, 55 patients had been in the hospital for less than 24 hours prior to the arrest and were, therefore, excluded. In the end, 66 medical files were reviewed. There were only 3 MET´s charts available for the included patients.

**Hospital characteristics**

Hospital São João is a tertiary hospital in Porto, Portugal. The hospital has a total of 53 intermediate/intensive care unit beds. In 2009, 42,990 patients were released from the various hospital departments and the mortality rate was 3.17%.

A MET was created in 1999. The team consists of a doctor and a nurse, both with training in advanced life support (ALS) as well as experience in management of critical patients. The MET is activated around 480 times a year, with 35-40% of these calls being for cardiac arrest.

**Patient characteristics**

The mean age was 69 years (table 1). Thirty eight (57.6%) were male and 28 (42.4%) were female. Fifty five percent were admitted to the hospital due to medical reasons, 35% due to surgical reasons and 10% due to trauma.

Regarding pre-existing morbidities, about 15% had history of myocardial infarction, 32% of heart failure, 33% had renal insufficiency, 20% respiratory insufficiency and 38% had diabetes mellitus (DM).

Five patients had two cardiac arrests, all but one on the same day. Three of them died during the second event and the other two survived to discharge. Only two patients had a history of cardiac arrest in previous hospital admissions.

**Event characteristics**

About 30% of patients had cardiac arrest in the Intensive Care Unit and 36% in the general inpatient area (table 1). Only 12% of patients had a shockable rhythm and it was not possible to ascertain the first rhythm in 24% of cases.

The mean inpatient days between admission and cardiac arrest was 15.5 days and between cardiac arrest and discharge was 22 days.

There were clinical abnormal observations in 83% of patients during the 24 hours prior to cardiac arrest, namely acute respiratory insufficiency or compromise in 42% and haemodynamic instability/hypotension in 49%.

**Outcomes**

It was possible to restore spontaneous circulation in 88% of patients (table 2). Twenty patients were discharged alive. Three of them died within one year after the event and 6 were lost in follow up. Therefore, one year survival after arrest of those discharged alive could be considered between 55% and 85%.

All patients with shockable rhythms had ROSC, but only 25% survived until discharge. Only one patient with ventricular fibrillation (VF) did not have a record of having received defibrillation.

The Charlson score did not differ significantly in patients with/without ROSC, although it was lower for patients without ROSC. The initial rhythm observed in cardiac arrest did not influence the ROSC after ALS or the proportion of patients who survived to hospital discharge (table 6). The rhythm did not influence the time of death and neither the crude OR nor the RR was statistically significant.

**Monitored vs. unmonitored**

In order to evaluate the differences between patients which were monitored at the time of event and those who were not, various parameters were compared between them (tables 3 and 4). Forty patients (61%) were monitored and 26 (39%) were unmonitored.

Most patients with a cardiac illness were monitored at the time of event ($p$=0.02), as were trauma patients. Pre-existing conditions did not differ between the two groups (p=0.25) and the Charlson score was not significantly different either.

Shockable rhythms occurred only in monitored patients, but asystole occurred in equal proportions (35% in both groups).

There were no significant differences in ROSC (OR=2.9, 95% CI: 0.637-13.54), survival 24hours past event (OR=1.12, 95% CI: 0.412-3.023) and at discharge (OR= 1.8, 95% CI: 0.586-5.503) between the monitored and unmonitored groups.

**Death in hospital vs. alive at discharge**

In order to identify possible predictive factors of poor prognosis after cardiac arrest, the patients who died in the hospital and those who survived until discharge were compared (table 5).

Mean age was not significantly different between the two groups. Cardiovascular risk factors and pre-existing conditions were not different either. The mean Charlson score was equal for the two groups. The monitored status was not related with better outcome.

The mean in-hospital days after cardiac arrest was significantly higher in survivors (45 days) than in non-survivors (13 days) (p=0.01).

## Discussion

Schein et al.[9] considered that one of the central questions of resuscitation research so far should be to what degree do in-hospital cardiopulmonary arrests represent predictable events. In this study, various possible predictive factors of cardiac arrest were analysed: previous morbidities, reason for admission and clinical anomalies preceding the event.

We also tried to compare the groups of monitored and unmonitored patients and of those who died in-hospital and those who survived to discharge, in order to, in the former case, uncover if monitoring could be a relevant factor for survival after arrest or if patients monitored and unmonitored that experience an arrest have different features; and in the latter, to make an attempt at describing predictors of survival and risk factors to poor outcome.

**Patient characteristics**

Approximately a third of the patients had a history of congestive heart failure or renal insufficiency or DM, three important comorbidities. In a study conducted on another Portuguese hospital, the prevalence of these comorbidities was somewhat different (40% cardiac disease, 16% chronic renal disease, 16% diabetes).[15] Concerning diabetes, it is regarded as a common feature in patients suffering in-hospital cardiac arrest and is considered a strong predictor of mortality.[16]

**Event characteristics**

Most patients (> 80%) had clinical anomalies related to airway, breathing, circulation or neurologic dysfunction, which is the ABCD of approach to a cardiac arrest.

The ACADEMIA study[17] also reported that 79.4% of cardiac arrests studied had evidence of abnormal physiology prior to the event, the most frequently reported abnormalities being low systolic blood pressure and a fall in Glasgow Coma Scale. Furthermore, a review of interventions aimed at anticipating and preventing in-hospital cardiac arrests concluded that critical physiological changes had been described in 51–86% of patients who had suffered a subsequent cardiopulmonary arrest in the general wards, often several hours before the arrest. The physiological changes described in the studies reviewed included respiratory insufficiency, change in mental status, hypotension, among others,[2] which is consistent with the results of this study.

The most common initial rhythm was asystole and almost 2/3 of the patients had an initial non-shockable rhythm, which is in agreement with other studies.[8,18]

**Outcomes**

The survival to discharge in this study was 30.3%. A previous study conducted also in Hospital São João in 1992 revealed a survival rate of only 5%,[19] however, the differences in the methodology do not permit making comparisons concerning a decrease in mortality after cardiac arrest in this hospital. Another study in a general nonteaching Portuguese hospital presented survival rates of 31% in a 2005-2006,[20] which is similar to our study.

In two studies from the USA based on the NRCPR (National Registry of Cardiopulmonary Resuscitation) the survival to discharge was around 17%[8] and 15.9%.[21] The difference between these figures and ours is probably mainly related to differences in methodology and sample size.

Furthermore, ROSC occurred in about 88% of patients, whereas in other studies it was only 44%.[1,8] This could translate an absence or lack of use of DNR, through the performance of resuscitation manoeuvres in patients that would otherwise not have an indication for such an aggressive treatment.

In relation to survival according to initial rhythm, our study reveals distinct results comparing to other studies, having a higher survival rate for non-shockable rhythms (21.7% for asystole and 42.1% for pulseless electrical activity (PEA) vs. 10% for asystole and PEA in the NRCPR study).[8] It is not possible to draw any specific conclusions from this difference, given that almost 25% of the patients in our study did not have a record of the initial rhythm, which reinforces the need for better registries concerning in-hospital cardiac arrests.

One year survival was about 55-85%, which is comparable with the 80% survival at one year obtained in another study.[22]

**Monitored vs. unmonitored**

The illness category is relevant in the monitored vs. unmonitored status at the time of event, given that all patients in the "surgical cardiac" and 9 out of 11 in the "medical cardiac" category were monitored, which demonstrates that these are usually considered critical patients. Brady et al.[23] also obtained significant differences in illness category between monitored and unmonitored patients.

Nevertheless, there were no statistically significant differences between the two groups when comparing for pre-existing conditions, cardiovascular risk factors or the Charlson score. This could just be a consequence of a small sample. In fact, Brady et al.[23] found differences in pre-existing conditions between monitored and/or witnessed and unmonitored/unwitnessed patients for pre-existing conditions such as myocardial infarction, history of heart failure, DM, respiratory insufficiency, pneumonia, renal insufficiency, cancer and major trauma, among others.

The outcomes were not different either. However, Brady et al.[23] described that patients who are witnessed and/or monitored at the time of cardiac arrest demonstrate a significantly higher rate of survival to hospital discharge compared to those patients who are neither monitored nor witnessed. Again, the small sample in this study could explain why there were no differences in outcome between the groups.

All patients that have an initial shockable rhythm were monitored, which could represent the earliest recognition of cardiac arrest and evaluation of rhythm. This preferable occurrence of shockable rhythms in monitored patients is in agreement with the study of Brady et al.,[23] where pulseless ventricular tachycardia and VF were also seen with increased frequency in the monitored units. It should be noted that there was a lack of registration of initial rhythm in 25% of monitored patients.

**Death in hospital vs. alive at discharge**

The average hospital length of stay after an index event was about 12 days for those who died in the hospital and about 45 days for survivors, which is considerably more than in the NRCPR study, which accounted an average hospital length of stay of 13.4 days for survivors and 1.5 days for those who died in the hospital.[8] This difference could, at least in part, be explained by our exclusion of patients who had an index event <24hours after admission in the hospital.

In this study, the registration of clinical anomalies before cardiac arrest was not significantly different between survivors and non-survivors. This might just be the result of a small sample, as, in another study, survival to hospital discharge was lower in those with abnormal vital signs (9%) compared to those with normal vital signs (20%) and those with no documentation of vital signs (14%).[7]

Regarding the Charlson score, there were no statistically significant differences between the two groups. It was not possible to find other studies evaluating the Charlson score in cardiac arrest patients, however a study comparing pre-arrest morbidity and outcome[24] found that there was no difference in survival associated with the presence or absence of morbidity before hospital admission, although there were differences between the morbidities.

Moreover, in this study, it does not appear to be any differences in pre-existing conditions between the group of patients who died and those who survived to discharge. Nevertheless, a meta-analysis of pre-arrest predictors of failure to survive[25] concluded that any malignancy, 'end-stage disease' and impaired renal function were co-morbid conditions significantly associated with non-survival. Non-cardiac diagnoses, pneumonia and trauma on admission were also associated with failure to survive to discharge, whereas cardiovascular diagnosis and co-morbidities were associated with a greater likelihood of survival. Larkin et

al.[21] also described a higher risk of death at the event and at discharge in patients with pre-existing hypotension, respiratory insufficiency, acute stroke, pneumonia and trauma.

The patients who died received defibrillation more frequently than those who survived ($p= 0.02$). This could just translate better registries for the patients who died or those patients had a worst clinical situation from the beginning.

**Limitations**

This study suffers from the typical problems associated with retrospective studies: the potential inaccuracy of data and its absence. The sample size is also small and may not be representative. Moreover, the MET´s compliance in obtaining more rigorous records in accordance with the Utstein model needs to be improved.

# Conclusions

This study, due to its small sample size, did not retrieve many results that can be transposed. However, it is possible to conclude that survival to discharge after in-hospital cardiac arrest in Hospital S. João in 2009 was 30.3% and one year survival was between 17% and 26%. It was not possible to find significant predictive factors for cardiac arrest. There were no significant differences between monitored and unmonitored patients regarding pre-existing conditions, characteristics of event and outcome. We could not find distinctive characteristics between patients who died in-hospital and those who survived, except for a longer in-hospital stay for survivors and more frequent defibrillation in non-survivors.

# Conflict of interest

The author has no conflicts of interest to declare.

# Acknowledgements

# References

1. Saklayen M, Liss H, Markert R. In-hospital cardiopulmonary resuscitation: Survival in 1 hospital and literature review. Medicine 1995;74:163-75.
2. Naeem N, Montenegro H. Beyond the intensive care unit: A review of interventions aimed at anticipating and preventing in-hospital cardiopulmonary arrest. Resuscitation 2005;67:13-23.
3. Granja C, Cabral G, Vieira A. Outcome of cardiac arrests in a Portuguese hospital-evaluation of a hospital cardiopulmonar resuscitation program at one year. Rev Port Cardiol 2001;20:943-56.
4. Jacobs I, Nadkarni V, Bahr J, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: Update and simplification of the Utstein templates for resuscitation registries. A statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council. Circulation 2004;110:3385-97.
5. Sandroni C, Nolan J, Cavallaro F, Antonelli M. In-hospital cardiac arrest: Incidence, prognosis and possible measures to improve survival. Intensive Care Medicine 2007;33:237-45.
6. Peatfield RC, Taylor D, Sillett RW, McNicol MW. Survival after cardiac arrest in hospital. The Lancet 1977;309:1223-5.
7. Skrifvars MB, Nurmi J, Ikola K, Saarinen K, Castrén M. Reduced survival following resuscitation in patients with documented clinically abnormal observations prior to in-hospital cardiac arrest. Resuscitation 2006;70:215-22.
8. Peberdy M. Cardiopulmonary resuscitation of adults in the hospital: A report of 14 720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. Resuscitation 2003;58:297-308.
9. Schein RM, Hazday N, Pena M, Ruben BH, Sprung CL. Clinical antecedents to in-hospital cardiopulmonary arrest. Chest 1990;98:1388-92.
10. Pearn J. Successful cardiopulmonary resuscitation outcome reviews. Resuscitation 2000;47:311-6.
11. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004;4:94.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
13. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. Journal of clinical epidemiology 2003;56:221-9.
14. Cummins RO, Chamberlain D, Hazinski MF, et al. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: The in-hospital 'Utstein style'. Circulation 1997;95:2213-39.
15. Mendes A, Carvalho F, Dias C, Granja C. In-hospital cardiac arrest: factors in the decision not to resuscitate. The impact of an organized in-hospital emergency system. Rev Port Cardiol 2009;28:131-41.
16. Petursson P, Gudbjörnsdottir S, Aune S, et al. Patients with a history of diabetes have a lower survival rate after in-hospital cardiac arrest. Resuscitation 2008;76:37-42.
17. Kause J, Smith G, Prytherch D, Parr M, Flabouris A, Hillman K. A comparison of antecedents to cardiac arrests, deaths and emergency intensive care admissions in Australia and New Zealand, and the United Kingdom--the ACADEMIA study. Resuscitation 2004;62:275-82.
18. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006;295:50-7.

19. Granja C, Marinho L, Abelha F, Morujão N, Castro-Tavares J. Ressuscitação cardio-pulmonar - estudo prospectivo. Revista Portuguesa de Medicina Intensiva 1994;4:22-7.
20. Campello G, Granja C, Carvalho F, Dias C, Azevedo L-F, Costa-Pereira A. Immediate and long-term impact of medical emergency teams on cardiac arrest prevalence and mortality: A plea for periodic basic life-support training programs *. Critical Care Medicine 2009;37:3054-61
21. Larkin GL, Copes WS, Nathanson BH, Kaye W. Pre-resuscitation factors associated with mortality in 49,130 cases of in-hospital cardiac arrest: A report from the National Registry for Cardiopulmonary Resuscitation. Resuscitation 2010;81:302-11.
22. Skrifvars MB, Castren M, Nurmi J, Thoren AB, Aune S, Herlitz J. Do patient characteristics or factors at resuscitation influence long-term outcome in patients surviving to be discharged following in-hospital cardiac arrest? Journal of Internal Medicine 2007;262:488-95.
23. Brady WJ, Gurka KK, Mehring B, Peberdy MA, O'Connor RE. In-hospital cardiac arrest: Impact of monitoring and witnessed event on patient survival and neurologic status at hospital discharge. Resuscitation 2011;82:845-52.
24. de Vos R, Koster RW, de Haan RJ, Oosting H, van der Wouw PA, Lampe-Schoenmaeckers AJ. In-hospital Cardiopulmonary Resuscitation: Prearrest Morbidity and Outcome. Arch Intern Med 1999;159:845-50.
25. Ebell MH, Afonso AM. Pre-arrest predictors of failure to survive after in-hospital cardiopulmonary resuscitation: a meta-analysis. Family Practice 2011;28:505-15.

# Tables

**Table 1. Patient and index event characteristics.**

| | |
|---|---|
| *N* | 66 |
| **Age (years)** | |
| Mean± S.D. | 69.3 ± 15.0 |
| Median (25th, 75th) | 73 (62.5, 80.0) |
| Range | 25 – 92 |
| **Sex *N* (%)** | |
| Male | 38 (57.6%) |
| Female | 28 (42.4%) |
| **Subject type – Inpatient *N* (%)** | |
| General Surgery | 6 (9.1%) |
| Cardiothoracic Surgery | 5 (7.6%) |
| Vascular Surgery | 2 (3.0%) |
| Orthopaedics – Trauma | 4 (6.1%) |
| Urology | 3 (4.6%) |
| Otorhinolaryngology | 1 (1.5%) |
| Burn Unit | 1 (1.5%) |
| Emergency Department | 2 (3.0%) |

| | |
|---|---|
| Internal Medicine | 11 (16.7%) |
| Intensive Care Unit | 18 (27.3%) |
| Infectious Diseases | 1 (1.5%) |
| Stroke Unit | 1 (1.5%) |
| Cardiology – Coronary Unit | 7 (10.6%) |
| Nephrology – Transplant Unit | 3 (4.7%) |
| Haematology | 1 (1.5%) |
| **Illness category *N* (%)** | |
| Medical, cardiac | 11 (16.7%) |
| Medical, noncardiac | 25 (38.0%) |
| Surgical, noncardiac | 19 (28.9%) |
| Surgical, cardiac | 4 (6.1%) |
| Trauma | 7 (10.6%) |
| **Pre-existing conditions * *N* (%)** | |
| Acute myocardial infarction | 8 (12.1%) |
| History of myocardial infarction | 10 (15.2%) |
| Arrhythmia | 9 (13.6%) |
| History of congestive heart failure | 21 (31.8%) |
| Acute neurologic event (nonstroke) | 6 (9.1%) |

| | |
|---|---|
| Acute stroke | 3 (4.7%) |
| Respiratory insufficiency | 13 (19.7%) |
| Pneumonia on admission | 4 (6.1%) |
| Sepsis on admission | 5 (7.7%) |
| Other infection on admission | 8 (12.1%) |
| Hepatic insufficiency | 3 (4.7%) |
| Renal insufficiency | 22 (33.3%) |
| Cancer (last 5 years) | 12 (18.2%) |
| Diabetes mellitus | 25 (37.9%) |
| Major trauma | 6 (9.1%) |
| Toxicological problem | 0 (0.0%) |
| None reported | 4 (6.1%) |
| **Event location *N* (%)** | |
| ICU | 20 (30.3%) |
| Inpatient | 24 (36.4%) |
| Emergency room | 7 (10.6%) |
| Diagnostic area | 1 (1.5%) |
| Operating room | 1 (1.5%) |
| Intermediate- Care Unit | 5 (7.7%) |

| | |
|---|---|
| Other | 3 (4.7%) |
| **Discovery status at time of event *N* (%)** | |
| Monitored | 40 (60.6%) |
| Unmonitored | 26 (39.4%) |
| **Cardiac arrest initial rhythm *N* (%)** | |
| VF/pulseless VT | 8 (12.14%) |
| PEA | 19 (28.8%) |
| Asystole | 23 (35.0%) |
| Unknown by documentation | 16 (24.2%) |
| **Inpatient days before cardiac arrest** | |
| Mean± S.D. | 15.5 ± 16.2 |
| Median (25th, 75th) | 8.5 (4.0, 24.3) |
| Range | 1.0 – 75.0 |
| **Inpatient days after cardiac arrest** | |
| Mean± S.D. | 22.3 ± 48.4 |
| Median (25th, 75th) | 7.5 (0.5, 19.3) |
| Range | 0 – 342 |
| **ROSC *N* (%)** | |
| Restored | 58 (87.8%) |

| | |
|---|---|
| Non sustained | 8 (12.2%) |
| **Advanced life support time procedures (minutes)** | |
| Mean± S.D. | 8.6 ± 10.4 |
| Median  (25th, 75th) | 6.0  (2.0 – 10.0) |
| Range | 2.0 – 60.0 |
| **Reason to suspend ALS *N* (%)** | |
| Re-established circulation | 50 (75.8%) |
| DNR/dead | 4 (6.1%) |
| Not possible | 1 (1.2%) |
| Not known (not registered) | 11 (16.7%) |
| **Clinical abnormal observations 24hours prior to cardiac arrest *N* (%)** | 55 (83.3%) |
| Airway obstruction | 4 (6.1%) |
| Acute respiratory insufficiency or compromise | 28 (42.4%) |
| Hypotension | 21 (31.8%) |
| Haemodynamic instability | 11 (16.7%) |
| Arrhythmia | 14 (21.2%) |
| CNS depression | 10 (15.2%) |
| Acute myocardial infarction or ischemia | 1 (1.5%) |

**Destination after cardiac arrest *N* (%)**

| | |
|---|---|
| ICU | 26 (39.4%) |
| Emergency room | 28 (42.4%) |
| Ward | 2 (3.0%) |
| Dead | 8 (12.1%) |
| Unknown/not registered | 2 (3.0%) |

**Interval time between cardiac arrest and death (days)\*\***

| | |
|---|---|
| Mean± S.D. | 19.5 ± 36.6 |
| Median  (25th, 75th) | 6.0 (1.0, 16.5) |
| Range | 0.0 – 160.0 |

*ALS:* Advanced Life Support; *CNS*: central nervous system; *DNR:* do not resuscitate; *ICU:* Intensive Care Unit*; PEA:* pulseless electric activity; *ROSC:* return of spontaneous circulation; *VT:* ventricular tachycardia; *VF:* ventricular fibrillation.

*\** Several patients had more than one pre-existing condition.

\*\* It includes follow up until 12 months after cardiac arrest.

**Table 2. Overall survival rate for index events and Charlson score for patients with/without ROSC**

| Cardiac arrest initial rhythm | ROSC after ALS N (%) | N (%) | p | Survival to hospital discharge N (%) | P |
|---|---|---|---|---|---|
| VF/pulseless VT | 8 (12.1%) | 8 (100.0%) | | 2 (25.0%) | |
| PEA | 19 (28.8%) | 17 (89.5%) | | 8 (42.1%) | |
| Asystole | 23 (35.0%) | 20 (87.0%) | | 5 (21.7%) | |
| Unknown by documentation | 16 (24.2%) | 13 (81.3%) | | 5 (31.3%) | |
| | | | 0.97 (1) | | 0.77 (2) |
| **Overall** | 66 | 58 (87.9%) | | 20 (30.3%) | |

**Charlson score (age adjusted)**

| | ROSC N= 58 (87.9%) | Without ROSC N=8 (12.1%) | p value |
|---|---|---|---|
| **Mean ± S.D.** | 5.7± 2.9 | 4.0 ± 3.3 | 0.18 |
| **Median (25th, 75th)** | 6.0 (4.0, 7.0) | 3.0 (1.3, 7.0) | |
| **Range** | 0.0 – 17.0 | 0.0 – 9.0 | |

*ALS:* advanced life support; *PEA:* pulseless electric activity; *ROSC*: return of spontaneous circulation; *VF*: ventricular fibrillation; *VT*: ventricular tachycardia.

(1) *p*=0.97 – cardiac arrest initial rhythms (asystole; PEA; VF/VT) and proportion of patients with ROSC.

(2) *p*=0.77 – initial rhythms (asystole; PEA; VF/VT) and proportion of patients surviving until hospital discharge.

**Table 3. Monitored and Unmonitored patients. Characteristics.**

Demographic characteristics, illness category, pre-existing conditions, cardiovascular risk factors, Charlson score (comorbidity index), cardiac arrest initial rhythm, time of arrest, drug therapy at the time of arrest, duration of event and in-hospital days after cardiac arrest.

|  | Monitored<br>*N* = 40 (60.6%) | Unmonitored<br>*N* = 26 (39.4%) | *p* value |
|---|---|---|---|
| **Age (years)** |  |  |  |
| Mean± S.D. | 68.3 ± 15.5 | 70.9 ± 14.4 | 0.52 |
| Median (25th, 75th) | 73.0 (64.0 – 80.0) | 72.0 (60.0 – 80.3) |  |
| Range | 25 – 88 | 26 – 92 |  |
| **Male sex *N* (%)** | 24 (60.0%) | 14 (54.0%) |  |
| Age, mean ± SD (years) | 65.9 ± 16.8 | 75.5 ± 11.5 | 0.06 |
| **Female sex *N* (%)** | 16 (40.0%) | 12 (46.2%) |  |
| Age, mean ± SD (years) | 72.1 ± 13.3 | 65.3 ± 15.9 | 0.23 |
| Male vs. Female |  |  | 0.62 |
| **Illness category *N* (%)** |  |  | 0.04 |
| Medical, cardiac | 9 (22.5%) | 2 (7.8%) |  |
| Medical, non-cardiac | 11 (27.5%) | 14 (54.0%) |  |
| Surgical, cardiac | 4 (10.0%) | 0 (0.0%) |  |
| Surgical, non-cardiac | 10 (25.0%) | 9 (34.6%) |  |

| | | | |
|---|---|---|---|
| Trauma | 6 (15.0%) | 1 (3.9%) | |
| Cardiac / non-cardiac | 13/27 | 2/24 | 0.02 |
| **Pre-existing conditions *N* (%)** | | | 0.25 |
| Acute myocardial infarction | 5 (12.5%) | 3 (11.5%) | |
| History of myocardial infarction | 7 (17.5%) | 3 (11.5%) | |
| Arrhythmia | 7 (17.5%) | 2 (7.8%) | |
| History of congestive heart failure | 11 (27.5%) | 10 (38.6%) | |
| Acute neurologic event (nonstroke) | 6 (15.0%) | 0 (0.0%) | |
| Acute stroke | 1 (2.5%) | 2 (7.8%) | |
| Respiratory insufficiency | 9 (22.5%) | 4 (15.4%) | |
| Pneumonia on admission | 1 (2.5%) | 3 (11.5%) | |
| Sepsis on admission | 2 (5.0%) | 3 (11.5%) | |
| Other infection on admission | 4 (10.0%) | 3 (11.5%) | |
| Hepatic insufficiency | 2 (5.0%) | 1 (3.9%) | |
| Renal insufficiency | 15 (37.5%) | 7 (26.9%) | |
| Cancer (last 5 years) | 7 (17.5%) | 5 (19.2%) | |
| Major trauma | 6 (15.0%) | 0 (0.0%) | |
| None reported | 1 (2.5%) | 3 (11.5%) | |

| | | | |
|---|---|---|---|
| **Cardiovascular risk factors *N* (%)** | | | 0.75 |
| Diabetes mellitus | 15 (37.5%) | 10 (38.5%) | |
| Tobacco | 6 (15.0%) | 8 (30.8%) | |
| Obesity | 2 (5.0%) | 3 (11.5%) | |
| Dislipidemia | 9 (22.5%) | 5 (19.2%) | |
| High blood pressure | 16 (40.0%) | 17 (65.4%) | |
| Without risk factors | 9 (22.5%) | 6 (23.1%) | |
| **Charlson score (age adjusted)** | | | |
| Mean ± S.D. | 5.3 ± 3.3 | 5.8 ± 2.5 | 0.28 (1) |
| Median (25th, 75th) | 5.0 (2.0, 7.0) | 6.0 (4.0, 7.0) | |
| Range | 0.0 – 17.0 | 0.0 – 11.0 | |
| **Cardiac arrest initial rhythm *N* (%)** | | | |
| Ventricular fibrillation | 6 (15.0%) | 0 (0.0%) | |
| Pulseless ventricular tachycardia | 2 (5.0%) | 0 (0.0%) | |
| Pulseless electrical activity | 8 (20.0%) | 11 (34.6%) | |
| Asystole | 14 (35.0%) | 9 (34.6%) | |
| Unknown | 10 (25.0%) | 6 (23.1%) | |
| **Time of event** (*) | | | 0.64 |
| 8:00 AM to 5:59 PM | 11 (27.5%) | 11 (34.6%) | |

| | | | |
|---|---|---|---|
| 6:00 PM to 10:59 PM | 6 (15.0%) | 5 (19.2%) | |
| 11:00 PM to 7:59 AM | 10 (25.0%) | 4 (15.4%) | |
| Weekend | 10 (25.0%) | 8 (30.8%) | |
| **Drugs administered during ALS** | | | 0.37 (2) |
| **N (%)** | | | |
| Adrenaline (Epinephrine) | 14 (35.0%) | 13 (50.0%) | |
| Dobutamine | 1 (2.5%) | 0 (0.0%) | |
| Dopamine | 0 (0.0%) | 0 (0.0%) | |
| Noradrenaline (Norepinephrine) | 3 (7.5%) | 1 (3.9%) | |
| Amiodarone | 8 (20.0%) | 0 (0.0%) | |
| Lidocaine | 2 (5.0%) | 0 (0.0%) | |
| Atropine | 9 (22.5%) | 14 (53.9%) | |
| Calcium chloride/calcium gluconate | 4 (10.0%) | 3 (11.5%) | |
| Fluid bolus for volume expansion | 0 (0.0%) | 4 (15.4%) | |
| Magnesium sulfate | 2 (5.0%) | 0 (0.0%) | |
| Sodium bicarbonate | 3 (7.5%) | 8 (30.8%) | |
| None/not registered | 25 (62.5%) | 9 (34.6%) | |
| **Event duration (minutes)** | | | |
| Mean ± S.D. | 7.4 ± 7.0 | 10.4 ± 13.9 | 0.24 |

| | Median (25th, 75th) | 5.0 (2.0 – 10.0) | 6.0 (4.0 – 10.0) | |
|---|---|---|---|---|
| Range | | 2.0 – 30.0 | 2.0 – 60.0 | |
| **In-hospital days after cardiac arrest** **(mean ±S.D.)** | | 25.3 ± 57.7 | 17.7 ± 29.5 | 0.54 |

*ALS:* Advanced Life Support

* Periods of time are according to usual nurse shifts.

1) Mann-Whitney U test

2) Considering only the use of adrenaline and atropine

**Table 4. Monitored and Non-Monitored patients. Outcomes.**

| | Total *N*=66 | Monitored *N*= 40 (60.6%) | Unmonitored *N* = 26 (39.4%) | *p* | OR (95% CI) |
|---|---|---|---|---|---|
| **ROSC >20 min** **N (%)** | 58 (87.9%) | 37 (56.1%) | 21 (31.8%) | 0.15 | 2.9 (0.637- 13.54) |
| **Survived 24 h past event** **N (%)** | 29 (43.9%) | 18 (27.3%) | 11 (16.7%) | 0.83 | 1.12 (0.412 - 3.023) |
| **Survived to discharge** **N (%)** | 20 (30.3%) | 14 (21.2%) | 6 (9.1%) | 0.70 | 1.8 (0.586 - 5.503) |
| **Death in-hospital N (%)** | 46 (69.7%) | 26 (65.0%) | 20 (76.9%) | 0.30 | |
| **Death during CPR manoeuvres N (%)** | 8 (12.1%) | 6 (15.0%) | 5 (19.2%) | 0.65 | |
| **Death in-hospital after CPR manoeuvres N (%)** | 38 (57.6%) | 23 (57.5%) | 15 (57.7%) | 0.18 | |

| | | | | |
|---|---|---|---|---|
| **Post-discharge cumulative N (%)** | 3 (4.5%) | 2 (5.0%) | 1 (3.9%) | |
| 0-3 months | 2 (3.0%) | 1 (2.5%) | 1 (3.9%) | |
| 0-6 months | 3 (4.5%) | 2 (5.0%) | 1 (3.9%) | |
| 0-12 months | 3 (4.5%) | 2 (5.0%) | 1 (3.9%) | |
| **Cause of death N (%)** | | | | |
| Cardiac | 8 (12.1%) | 6 (15.0%) | 2 (7.7%) | |
| Other medical cause | 36 (54.6%) | 19 (47.5%) | 17 (65.4%) | |
| Trauma | 3 (4.6%) | 3 (7.5%) | 0 (0.0%) | |
| Surgical cause | 2 (3.0%) | 0 (0.0%) | 2 (7.7%) | |
| Other | 1 (1.2%) | 1 (2.5%) | 0 (0.0%) | |
| Cardiac/non-cardiac cause | | 6/23 | 2/19 | 0.29 |
| **Alive at discharge N (%)** | 20 (30.3%) | 14 (35.0%) | 6 (23.1%) | |
| **Alive after 12 months N (%)** | 11 (16.7%) | 7 (17.5%) | 4 (15.4%) | |
| **Lost in follow up N (%)** | 6 (9.1%) | 5 (12.5%) | 1 (5.0%) | |

*OR:* odds ratio; *ROSC:* return of spontaneous circulation.

**Table 5. Death in-hospital and patients alive at discharge.**

Demographic characteristics, illness category, pre-existing conditions, cardiovascular risk factors, Charlson score (comorbidity index), previous heart disease, monitored and unmonitored patients, infectious diseases, in-hospital days after cardiac arrest, cardiac arrest initial rhythm, defibrillation, time of event and duration, clinical abnormal observations prior to cardiac arrest.

| | Death in-hospital | Alive at discharge | |
|---|---|---|---|
| | | | *p* value |
| | *N* = 46 (69.7%) | *N* =20 (30.3%) | |
| **Age (years)** | | | |
| Mean± S.D. | 68.6 ± 16.0 | 70.8 ± 12.9 | 0.59 |
| Median (25th, 75th) | 73 (59.8, 80.0) | 82 (64.8, 80.8) | |
| Range | 25 – 92 | 29 – 86 | |
| **Sex** | | | 0.79 |
| Male | 26 (56.5%) | 12 (26.1%) | |
| Female | 20 (43.5%) | 8 (17.4%) | |
| **Illness category *N* (%)** | | | |
| Medical, cardiac | 7 (15.2%) | 4 (8.7%) | |
| Medical, non-cardiac | 21 (45.8%) | 4 (8.7%) | |
| Surgical, cardiac | 12 (26.1%) | 7 (15.2%) | |
| Surgical, non-cardiac | 2 (4.4%) | 2 (4.4%) | |
| Trauma | 4 (8.7%) | 3 (6.5%) | |

| | | | |
|---|---|---|---|
| Cardiac / non-cardiac | 19/27 | 11/9 | 0.30 |
| **Pre-existing conditions *N* (%)** | | | 0.70 |
| Acute myocardial infarction | 5 (11.0%) | 3 (15.0%) | |
| History of myocardial infarction | 6 (13.0%) | 4 (20.0%) | |
| Arrhythmia | 4 (8.7%) | 5 (25.0%) | |
| History of congestive heart failure | 15 (32.6%) | 6 (3.0%) | |
| Acute stroke | 2 (4.4%) | 1 (5.0%) | |
| Respiratory insufficiency | 7 (15.2%) | 6 (3.0%) | |
| Pneumonia on admission | 2 (4.4%) | 1 (5.0%) | |
| Sepsis on admission | 5 (11.0%) | 0 (0.0%) | |
| Other infection on admission | 5 (11.0%) | 2 (10.0%) | |
| Hepatic insufficiency | 3 (6.5%) | 0 (0.0%) | |
| Renal insufficiency | 17 (37.1%) | 5 (25.0%) | |
| Cancer (last 5 years) | 9 (19.6%) | 3 (15.0%) | |
| Major trauma | 3 (6.5%) | 3 (15.0%) | |
| None reported | 2 (4.4%) | 2 (10.0%) | |
| **Cardiovascular risk factors *N* (%)** | | | 0.77 |
| Diabetes Mellitus | 16 (34.8%) | 9 (45.0%) | |

| | | | |
|---|---|---|---|
| Tobacco | 7 (15.2%) | 7 (35.0%) | |
| Obesity | 3 (6.52%) | 2 (10.0%) | |
| Dislipidemia | 8 (17.4%) | 6 (3.0%) | |
| High blood pressure | 23 (50.0%) | 10 (5%) | |
| Without risk factors | 11 (23.9%) | 4 (20.0%) | |
| With/ Without cardiovascular risk factors | 35/11 | 16/4 | 0.73 |
| **Charlson score (age adjusted)** | | | |
| Mean ± S.D. | 5.5 ± 3.2 | 5.5 ± 2.6 | 0.91 (1) |
| Median (25th, 75th) | 5.0 (3.0, 7.0) | 6.0 (4.3, 7.0) | |
| Range | 0.0 – 17.0 | 0.0 – 11.0 | |
| **Previous heart disease *N* (%)** | 16 (34.8%) | 12 (60.0%) | 0.06 |
| **Monitored *N* (%)** | 26 (56.5%) | 14 (70.0%) | |
| **Unmonitored *N* (%)** | 20 (43.6%) | 6 (3.0%) | |
| **Monitored/unmonitored** | | | 0.30 |
| **Infections (admission + in-hospital) *N* (%)** | | | 0.50 |
| Pneumonia | 19 (41.3%) | 9 (45.0%) | |
| Sepsis/septic shock | 20 (43.6%) | 5 (25.0%) | |
| Bacteraemia | 8 (17.4%) | 6 (3.0%) | |
| Other | 15 (32.6%) | 6 (3.0%) | |

| | | | |
|---|---|---|---|
| **In-hospital days after cardiac arrest** | | | |
| Mean ±S.D. | 12.7 ± 26.3 | 44.6 ± 75.2 | 0.01 |
| Median (25th, 75th) | 2.8 (0.1, 14.1) | 17.5 (8.0, 52.0) | |
| Range | 0.0 – 121.0 | 5.0 – 342.0 | |
| **Cardiac arrest initial rhythm _N_ (%)** | | | 0.54 |
| VF/ pulseless VT | 6 (13.1%) | 2 (10.0%) | |
| Pulseless electrical activity | 11 (23.9%) | 8 (40.0%) | |
| Asystole | 18 (39.1%) | 5 (25.0%) | |
| Unknown | 11 (23.9%) | 5 (25.0%) | |
| **Defibrillation _N_ (%)** | | | |
| Patients who received defibrillation | 15 (37.5%) | 1 (3.9%) | 0.02 |
| **Time of event (*) _N_ (%)** | | | |
| 8:00 AM to 5:59 PM | 15 (32.6%) | 7 (35.0%) | |
| 6:00 PM to 10:59 PM | 9 (19.6%) | 2 (10.0%) | |
| 11:00 PM to 7:59 AM | 11 (23.9%) | 3 (15.0%) | |
| Weekend | 15 (32.6%) | 3 (15.0%) | |
| **Event duration (minutes)** | | | |
| Mean ± S.D. | 7.5 ± 7.2 | 10.7 ± 14.2 | 0.23 |
| Median  (25th, 75th) | 5.0 (2.0, 10.5) | 8.0 (4.0, 10.0) | |

| | | | |
|---|---|---|---|
| Range | 2.0 – 35.0 | 2.0 – 60.0 | |
| **Clinical abnormal observations**<br><br>**24hours prior to cardiac arrest *N* (%)** | 40 (87.0%) | 15 (75.0%) | 0.57 |
| Airway obstruction | 2 (4.3%) | 2 (10.0%) | |
| Acute respiratory insufficiency or compromise | 18 (39.1%) | 10 (50.0%) | |
| Hypotension | 15 (32.6%) | 6 (30.0%) | |
| Haemodynamic instability | 9 (19.6%) | 2 (10.0%) | |
| Arrhythmia | 10 (21.7%) | 4 (20.0%) | |
| CNS depression | 9 (19.6%) | 1 (5.0%) | |

*CNS:* central nervous system; *VF*: ventricular fibrillation; *VT*: ventricular tachycardia.

* Periods of time are according to usual nurse shifts.

(1) Mann-Whitney U test

**Table 6. Pre-resuscitation facts and association with outcome (*N*=66)**

| Event specific data | Prevalence % (*N*) | % (*N*) Died at event | % (*N*) Died at discharge | Crude OR of discharge mortality; 95% CI | RR of discharge mortality ; 95% CI * |
|---|---|---|---|---|---|
| Monitored | 60.6% (40) | 15.0% (6) | 65.0% (26) | 0.56 (0.18-1.71) | 0.85 (0.62-1.15) |
| **First documented pulseless rhythm** | | | | | |
| Asystole | 34.9% (23) | 13.0% (3) | 78.3% (18) | 1.93 (0.60-6.23) | 1.20 (0.88-1.64) |
| PEA | 28.8% (19) | 5.3% (1) | 57.9% (11) | 0.47 (0.15-1.45) | 0.78 (0.51-1.18) |
| VF or pulseless VT | 12.1% (8) | 0.0 % (0) | 75.0% (6) | 1.35 (0.25-7.35) | 1.09 (0.70-1.68) |
| Missing/unknown | 24.2% (16) | 25.0% (4) | 68.8% (11) | | |

*OR:* odds ratio*; PEA:* pulseless electric activity; *RR:* relative risk; *VF*: ventricular fibrillation; *VT*: ventricular tachycardia;

*All values of *p*>0.05

# Anexo

**Normas da revista:** Resuscitation

**Guide for Authors**

An interdisciplinary journal for the dissemination of clinical and basic science research relating to cardiopulmonary resuscitation.

*Resuscitation* is a monthly interdisciplinary medical journal and is the official journal of the European Resuscitation Council. The papers published deal with the aetiology, pathophysiology and prevention of cardiac arrest, resuscitation training, clinical resuscitation, and experimental resuscitation research. Review articles and Letters to the Editor, particularly relating to articles previously published in Resuscitation, are welcome. We no longer publish case reports as papers but a case of exceptional interest and originality may be considered for publication if submitted in the form of a letter to the editor.

**Editorial policy**

The originality of content of papers submitted and the quality of the work on which they are based is the prime consideration of the editors. The paper should deal with original material, neither previously published nor being considered for publication elsewhere, except in special circumstances agreed with the Editor-in-Chief. Most papers are assigned to an editor and sent for peer review; papers may be returned to authors as accepted, for reconsideration after revision, or rejection. The reviewers name may or may not be revealed to the author(s), depending on the reviewer's preference. The decision of the Editor-in-Chief regarding acceptance or rejection is final. Papers that are not within the scope of the journal or are far below the standard for publication in *Resuscitation* will be rejected by the Editors without obtaining peer review. Papers that simply describe a clinical trial protocol will be rejected. Resuscitation operates a word limit for all articles as detailed in the table below. Manuscripts will be returned to the author if the word count is exceeded.

WORD LIMIT (excluding abstract and references)

Original Paper* 3000; Short Paper* 1500; Review* 4000; Commentary and Concepts* 2000; Editorial 1200; Letter to Editor 500

TABLES/ILLUSTRATION LIMIT

Original Paper* 6; Short Paper* 3; Review* 8; Commentary and Concepts* 3; Editorial 1; Letter to Editor 1.

REFERENCE LIMIT

Original Paper* 40; Short Paper* 20; Review* 75; Commentary and Concepts* 20; Editorial 30; Letter to Editor 5.

*option for supplementary on line materials

**Guide for Authors**

These guidelines generally follow the 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals' The complete document appears at http://www.icmje.org.

These instructions for authors can also be found on www.elsevier.com/wps/find/journaldescription.cws_home/505959/description#description.

**Submission of papers**

Authors must submit their original manuscript and figures online via http://ees.elsevier.com/resus which is the Elsevier web-based submission and peer-review system. You will find full instructions located on this site - a Guide for Authors and a Guide for Online Submission. Please follow these guidelines to prepare and upload your article.

Once the manuscript has been uploaded, our system automatically generates an electronic PDF proof, which is then used for reviewing. All correspondence, including notification of the Editor's decision and requests for revisions, will be managed via this system. Authors may also track the progress of their paper using this system to final decision.

If you have any problems submitting your paper through this system, please contact the Editorial Office on: e-mail: resus@elsevier.com; tel: +44 (0)1865 843620; fax: +44 (0)1865

843992.

Upon acceptance of an article, authors will be asked to sign a 'Journal Publishing Agreement' (for more information on this and copyright see http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Once an article has been accepted, the uncorrected provisional pdf will be published immediately online pending publication of the fully formatted final version.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions).

If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.

Your manuscript should be submitted together with a covering letter which should be signed by the corresponding author on behalf of all authors and should include: * A statement that all authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or is the chair of the department who provided only general support.

Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

* A statement that the manuscript, including related data, figures and tables, has not been published previously and that the manuscript is not under consideration elsewhere.

* The names and contact addresses (including e-mail) of two potential reviewers that have not been involved in the design, performance and discussion of the data and are not a co-worker. These may or may not be used at the Editor's discretion. You may also mention persons who you would prefer not to review your paper.

**Conflict of interest**

At the end of the text, under a subheading 'Conflict of interest statement' all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If an author has no conflict of interest, state this explicitly.

**Role of the funding source**

All sources of funding must be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Please see http://www.elsevier.com/funding

**Randomised controlled trials**

*Resuscitation* has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which requires, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the

abstract of the article. For this purpose, a clinical trial is defined as any research project that assigns human subjects prospectively to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials), and manikin or laboratory studies would be exempt. Further information can be found at www.icmje.org.

**Ethics and Patient Consent**

Work on human beings that is submitted to *Resuscitation* must comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript must contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that, where appropriate, subjects gave informed consent to the work. Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.

Identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve, however, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of

anonymity.

Studies involving experiments with animals must state that their care was in accordance with institution guidelines.

**Structure of papers**

Papers must comply with the word count and figure, table and reference limit listed above.

All papers must include a separate title page documenting: authors' full names, academic and professional affiliations and complete addresses; the name and address of the corresponding author; the word count of the paper and the abstract (if applicable).

Original papers, reviews and short papers must include an abstract of no longer than 250 words. This should be a structured abstract listing the aim of the study (or review), the methods (or 'data sources' for a review), the results and the conclusion. Commentaries must include a brief abstract of no more than 100 words that summarises the key points. Papers must be written concisely and conform to the style of Resuscitation. They should be clearly divided into sections: Introduction; Methods; Results; Discussion; Conclusions; Conflicts of Interest; Acknowledgments; References; Legends to figures. For review papers and commentaries use appropriate sub-headings instead of methods, results and discussion.

**Language**

All papers submitted to the Editor-in-Chief must use 'English' spelling e.g. haemodynamic, ischaemia, aetiology, oesophagus etc. Use generic names for all drugs. The term 'adrenaline' is preferred to 'epinephrine': for the first use only, 'adrenaline' should be followed by 'epinephrine' in brackets (parentheses). Similar arrangements apply to noradrenaline and norepinephrine.

*Resuscitation* has an international readership: keep abbreviations to a minimum and confine as much as possible to those in regular use. Too many abbreviations make reading difficult. Abbreviations of units must conform to the International System of Units (SI), for

example, kg, g, mg, cm, mm, ml, mg kg-1. Plurals have the same abbreviations as used for the singular. If non-regular abbreviations are used supply a list of these with their definitions as a footnote to page 1. Do not use abbreviations of this type in the Abstract.

**Supplementary data (including multimedia and video)**

The journal accepts electronic supplementary material to support and enhance your scientific research. Supplementary files allow the author to submit supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more, which will be published online alongside the electronic version of your article. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of the recommended file formats (for detailed guidance on formats for supplementary files go to http://www.elsevier.com/wps/find/authorsview.authors/file_formats).

Insert citations in superscript (after punctuation) and list the references on a separate sheet in numerical sequence in the order in which they are first mentioned in the text. References cited only in tables or figure legends are numbered in accordance with the sequences established by the first identification in the text of the particular figure or table. List all authors when there are six or less; when there are seven or more, list the first three, then 'et al'. Abbreviate the titles of journals according to the style used in Index Medicus. The list of journals can be found at http://www.nlm.nih.gov/tsd/serials/terms_cond.html.

The following are sample references:

Articles in Journals

1. Ross P, Nolan J, Hill E, Dawson J, Whimster F. The use of AEDs by police officers in the City of London. Resuscitation 2001;50:141-6.

2. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.

Books

3. Armitage P. Statistical methods in medical research. London, Blackwell Scientific Publications, 1971.

Chapters

4. Phillips SJ, Whisnant JP Hypertension and stroke. In Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis, and management. 2nd ed. New York, Raven Press, 1995: 465-78.

References to electronic publications

Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions. Guidelines for healthcare providers. London, Resuscitation Council (UK), 2008. (Accessed 11 August 2008, at http://www.resus.org.uk/pages/reaction.pdf)

Numbered references to personal communications, unpublished data or manuscripts either 'in preparation' or 'submitted for publication' are unacceptable. If essential, include this material at the appropriate place in the text. Illustrations must be in a form and condition suitable for reproduction. The illustration should bear the manuscript titles and be numbered in Arabic numerals according to the sequence of their appearance in the text, where they should be referred to as Fig. 1, Fig. 2, etc. Line-drawings should be drawn at least twice the size of their final intended appearance. Lettering should be clear and of adequate size to be legible after reduction. The extent of reduction will be determined by the publisher, but in general the same reduction will be applied to all figures in the same paper. Reproduction in colour is subject to approval by the Editor-in-Chief and Publisher. The extra costs of print colour reproduction will be charged to the author(s) although colour reproduction online is free of charge. Each illustration must have a legend that is typed with double spacing on a separate page and beginning with the number of the illustration they refer to.

Tables of numerical data are typed (also with double-spacing) on a separate page,

numbered in sequence in Arabic numerals (Table 1, 2, etc.) and provided with a heading, a legend, and referred to the text as Table 1, Table 2, etc.

Elsevier has negotiated with several language editing companies to provide language editing services to our authors at competitive rates. Asia Science Editing, Diacritech Language Editing Services, Edanz Editing, International Science Editing, ScienceDocs Editing Services and SPI Publisher Services provide language and copy editing services globally to authors who would like assistance either before they submit an article for peer review or before it is accepted for publication.

**Statistical Methods**

* Use nonparametric methods to compare groups when the distribution of the dependent variable is not normal.

* Use measures of uncertainty (e.g. confidence intervals) consistently.

* Report two-sided P values except when one-sided tests are required by study design (e.g., non-inferiority trials). Report P values larger than 0.01 to two decimal places, those between 0.01 and 0.001 to three decimal places; report P values smaller than 0.001 as P<0.001.

* All randomised controlled trials submitted for publication in Resuscitation should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information.

**Funding body agreements and policies**

Elsevier has established agreements and developed policies to enable authors who publish in Elsevier journals to comply with potential manuscript archiving requirements as specified as conditions of their grant awards from the funding bodies: Arthritis Research Campaign (UK); Austrian Science Fund (FWF); British Heart Foundation (UK); BBSRC; Cancer Research (UK); Chief Scientist Office; Department of Health (UK);Howard Hughes Medical Institute (US); Medical Research Council (UK); National Institutes of Health

**Authors' rights**

As an author you (or your employer or institution) retain certain rights; for details access: http://www.elsevier.com/wps/find/authorshome.authors/authorsrights.

**Author Enquiries**

The facility to track accepted articles and set up e-mail alerts to inform you when an article's status changes can be found at: http://authors.elsevier.com/TrackPaper.html. There is also information on artwork guidelines, copyright information, and answers to frequently asked questions.

**Proofs**

One set of page proofs in PDF format will be sent by e-mail to the corresponding author. Elsevier now sends PDF proofs that can be annotated; for this you will need to download Adobe Reader version 8. Instructions on how to annotate PDF files will accompany the proofs.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Once accepted for publication, significant changes to the article will be considered at this stage only with permission from the Editor-in-Chief. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proof reading is

solely your responsibility. Elsevier may proceed with the publication of your article if no response is received.

All questions relating to proofs should be directed to: Elsevier Ltd., Stover Court, Bampfylde Street, Exeter, Devon, EX1 2AH, UK. E mail l.machin@elsevier.com

**Reprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Paper offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.